Toronto’s AmacaThera is preparing clinical trials of a drug delivery hydrogel that could diminish the need for prescription opioid painkillers after surgery.

AmacaThera, a Canada-based drug release hydrogel developer based on University of Toronto research, has raised C$3.3m ($2.5m) in a seed round co-led by drug design services provider Viva Biotech. Sprout BioVentures co-led the round, with participation from early-stage investment fund Grey Sky Venture Partners. The deal remains open to additional investors, with a second close…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.